PROMIS displays strong construct validity in pediatric and adult patients with idiopathic inflammatory myopathies
PROMIS offers a nuanced view of HRQoL that traditional disease assessments do not adequately capture. PROMIS has good construct validity and it may be more sensitive than legacy HRQoL measures. These findings support the incorporation of PROMIS into the assessment of IIM/JIIM to address comprehensive patient well-being.
Authors
- Julie Fuller
- Lisa G. Rider (ORCID: https://orcid.org/0000-0002-6912-2458)
- Vy Do (ORCID: https://orcid.org/0000-0002-4322-4413)
- Kelly Rouster‐Stevens (ORCID: https://orcid.org/0000-0002-7855-9168)
- Sara Sabbagh (ORCID: https://orcid.org/0000-0003-3176-9958)
- Adam I. Schiffenbauer (ORCID: https://orcid.org/0000-0001-9964-9966)
- Ke Yan (ORCID: https://orcid.org/0000-0001-6599-4622)
- Melodee Liegl
- Emma Austenfeld (ORCID: https://orcid.org/0000-0002-6723-7358)
Institutions
- National Institutes of Health (US)
- Medical College of Wisconsin (US)
- Texas Scottish Rite Hospital for Children (US)
- National Institute of Environmental Health Sciences (US)
- Quantitative BioSciences (US)
- National Institute of Nursing Research (US)
- Children's Healthcare of Atlanta (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1093/rheumatology/keaf502
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00